Ad-hoc Publications

To view the PDF documents you will need the Acrobat Reader. Please click here to download the free Adobe Acrobat Reader software.


September 29, 2011
Phase III Study of Bayer’s Rivaroxaban in Patients with Acute Coronary Syndrome Meets Primary Efficacy EndpointDownload ( PDF, 87 KB )collect
September 6, 2011
Bayer AG: FDA has published documents for discussion at the Advisory Committee on the new drug application for RivaroxabanDownload ( PDF, 124 KB )collect


October 31, 2010
Bayer AG: Phase III ROCKET AF Study of Rivaroxaban meets its primary efficacy endpoint with Comparable Safety vs. WarfarinDownload ( PDF, 41 KB )collect
August 4, 2010
Bayer AG: Rivaroxaban Meets Primary Endpoint in Long-Term Phase III EINSTEIN-DVT StudyDownload ( PDF, 37 KB )collect


September 15, 2009Dr. Marijn E. Dekkers to be new CEO of Bayer from October 1, 2010Download ( PDF, 35 KB )collect


March 3, 2008Bayer AG: Court Decides against the Company’s Yasmin® Patent Download ( PDF, 36 KB )collect


April 26, 2007Bayer exceeds consensus estimates for Q1 2007Download ( PDF, 63 KB )collect

Previous ad-hoc publications can be found in the Archive.

Last updated: November 14, 2013 Copyright © Bayer AG